# In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both?

> **NCT03174912** · PHASE4 · COMPLETED · sponsor: **Ankara Training and Research Hospital** · enrollment: 400 (actual)

## Conditions studied

- Bladder Cancer
- Disease Progression
- Recurrent Bladder Cancer

## Interventions

- **PROCEDURE:** Intravesical BCG instillation

## Key facts

- **NCT ID:** NCT03174912
- **Lead sponsor:** Ankara Training and Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01-01
- **Primary completion:** 2016-12-31
- **Final completion:** 2016-12-31
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2017-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03174912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03174912, "In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both?". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03174912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*